Antibody engineering to develop new antirheumatic therapies

被引:23
作者
Isaacs, John D. [1 ,2 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Wilson Horne Immunotherapy Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
IMMUNOGLOBULIN VARIABLE DOMAINS; COMPLEMENT-MEDIATED LYSIS; AFFINITY HUMAN-ANTIBODIES; ANTITUMOR NECROSIS FACTOR; PHASE-I TRIAL; MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; EFFECTOR FUNCTIONS; CYTOKINE STORM;
D O I
10.1186/ar2594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immunosuppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments.
引用
收藏
页数:11
相关论文
共 70 条
[31]  
Isaacs JD, 1998, J IMMUNOL, V161, P3862
[32]   A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans [J].
Isaacs, JD ;
Wing, MG ;
Greenwood, JD ;
Hazleman, BL ;
Hale, G ;
Waldmann, H .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 106 (03) :427-433
[33]   HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR RHEUMATOID-ARTHRITIS [J].
ISAACS, JD ;
WATTS, RA ;
HAZLEMAN, BL ;
HALE, G ;
KEOGAN, MT ;
COBBOLD, SP ;
WALDMANN, H .
LANCET, 1992, 340 (8822) :748-752
[34]   GUIDING THE SELECTION OF HUMAN-ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN [J].
JESPERS, LS ;
ROBERTS, A ;
MAHLER, SM ;
WINTER, G ;
HOOGENBOOM, HR .
BIO-TECHNOLOGY, 1994, 12 (09) :899-903
[35]   REPLACING THE COMPLEMENTARITY-DETERMINING REGIONS IN A HUMAN-ANTIBODY WITH THOSE FROM A MOUSE [J].
JONES, PT ;
DEAR, PH ;
FOOTE, J ;
NEUBERGER, MS ;
WINTER, G .
NATURE, 1986, 321 (6069) :522-525
[36]   The protection receptor for IgG catabolism is the beta(2)-microglobulin-containing neonatal intestinal transport receptor [J].
Junghans, RP ;
Anderson, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) :5512-5516
[37]   Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides:: the high-mannose, hybrid, and complex types [J].
Kanda, Yutaka ;
Yamada, Tsuyoshi ;
Mori, Katsuhiro ;
Okazaki, Akira ;
Inoue, Miho ;
Kitajima-Miyama, Kazuko ;
Kuni-Kamochi, Reiko ;
Nakano, Ryosuke ;
Yano, Keiichi ;
Kakita, Shingo ;
Shitara, Kenya ;
Satoh, Mitsuo .
GLYCOBIOLOGY, 2007, 17 (01) :104-118
[38]   Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes [J].
Keymeulen, B ;
Vandemeulebroucke, E ;
Ziegler, AG ;
Mathieu, C ;
Kaufman, L ;
Hale, G ;
Gorus, F ;
Goldman, M ;
Walter, M ;
Candon, S ;
Schandene, L ;
Crenier, L ;
De Block, C ;
Seigneurin, JM ;
De Pauw, P ;
Pierard, D ;
Weets, I ;
Rebello, P ;
Bird, P ;
Berrie, E ;
Frewin, M ;
Waldmann, H ;
Bach, JF ;
Pipeleers, D ;
Chatenoud, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2598-2608
[39]  
KEYSTONE EC, 2008, ANN RHEUM DIS 1211
[40]   Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study [J].
Keystone, Edward ;
van der Heijde, Desiree ;
Mason, David, Jr. ;
Landewe, Robert ;
van Vollenhoven, Ronald ;
Combe, Bernard ;
Emery, Paul ;
Strand, Vibeke ;
Mease, Philip ;
Desai, Chintu ;
Pavelka, Karel .
ARTHRITIS AND RHEUMATISM, 2008, 58 (11) :3319-3329